- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01580293
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)
A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A
Haemophilia A is an inherited disorder in which one of the proteins, Factor VIII, needed to form blood clots is missing or not present in sufficient levels. In a person with haemophilia A, the clotting process is slowed and the person experiences bleeds that can result in serious problems and potential disability.
The current standard treatment for severe haemophilia A is regularly scheduled infusion of FVIII to keep levels high enough to prevent bleeding. Due to the short half-life of FVIII, prophylaxis may require treatment as often as every other day.
In this trial safety and efficacy of a long-acting recombinant factor VIII molecule is evaluated in subjects with severe Hemophilia A.
120-140 patients will receive open label treatment with long-acting rFVIII either on-demand to treat bleeds or prophylactically for 36 weeks in the main trial plus an optional extension to continue treatment for at least 100 total exposure days (ED). Patients on prophylactic treatment will receive study drug at dosing intervals between once and twice a week depending on their observed bleeding. Patients will attend the treatment centre for routine blood samples and be required to keep an electronic diary.
Male patients aged 12-65, with severe hemophilia A, previously treated with FVIII for at least 50 exposure days may be eligible for this study.
Study Overview
Detailed Description
Subjects in prophylactic treatment arms will undergo clinical evaluation at 10 weeks. Those with adequate control of bleeding will undergo randomization to every 5 or 7 day infusion. Those with continued bleeding will remain in treatment arm and have an increase in dose.
Part B-major surgery - optional sub study included to collect information on efficacy of BAY94-9027 in major surgical setting. Due to rarity of surgery in this population, enrollment to this sub-study may be independent of participation in main study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Wien, Austria, 1090
-
-
-
-
-
Brugge, Belgium, 8000
-
-
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
-
-
-
-
Antioquia
-
Medellin, Antioquia, Colombia, 050030
-
-
Atlántico
-
Baranquilla, Atlántico, Colombia, 080020
-
-
-
-
-
Aarhus N, Denmark, 8200
-
-
-
-
-
BRON cedex, France, 69677
-
Marseille, France, 13005
-
Reims Cedex, France, 51092
-
Rennes Cedex, France, 35033
-
-
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69004
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Germany, 53127
-
-
-
-
-
Ramat Gan, Israel, 5262000
-
-
-
-
Campania
-
Napoli, Campania, Italy, 80131
-
-
Lazio
-
Roma, Lazio, Italy, 00161
-
-
Lombardia
-
Milano, Lombardia, Italy, 20122
-
-
Piemonte
-
Torino, Piemonte, Italy, 10126
-
-
-
-
-
Hiroshima, Japan, 734-8551
-
-
Aichi
-
Nagoya, Aichi, Japan, 466-8560
-
-
Hyogo
-
Nishinomiya, Hyogo, Japan, 663-8501
-
-
Nara
-
Kashihara, Nara, Japan, 634-8522
-
-
Tokyo
-
Shinjuku-ku, Tokyo, Japan, 160-0023
-
Suginami, Tokyo, Japan, 167-0035
-
-
-
-
-
Daejeon, Korea, Republic of, 35233
-
Seoul, Korea, Republic of, 05278
-
Seoul, Korea, Republic of, 03722
-
-
Busan Gwang''yeogsi
-
Busan, Busan Gwang''yeogsi, Korea, Republic of, 49241
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
-
Den Haag, Netherlands, 2545 CH
-
Groningen, Netherlands, 9713 GZ
-
Maastricht, Netherlands, 6229 HX
-
-
-
-
-
Oslo, Norway, 0372
-
-
-
-
-
Wroclaw, Poland, 50-367
-
-
-
-
-
Timisoara, Romania, 300011
-
-
-
-
-
Singapore, Singapore, 119228
-
Singapore, Singapore, 169608
-
Singapore, Singapore, 229 899
-
-
-
-
-
Changhua, Taiwan, 50006
-
Taipei, Taiwan, 100
-
Taipei, Taiwan, 11217
-
-
-
-
-
Ankara, Turkey, 06100
-
Izmir, Turkey, 35100
-
-
-
-
-
London, United Kingdom, SE1 7EH
-
Sheffield, United Kingdom, S10 2JF
-
-
Vale Of Glamorgan, The
-
Newcastle Upon Tyne, Vale Of Glamorgan, The, United Kingdom, NE1 4LP
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85724-5024
-
-
California
-
Sacramento, California, United States, 95817
-
San Diego, California, United States, 92103-8651
-
-
Florida
-
Jacksonville, Florida, United States, 32207
-
Miami, Florida, United States, 33136
-
-
Illinois
-
Chicago, Illinois, United States, 60612
-
-
Michigan
-
Detroit, Michigan, United States, 48202
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
-
-
New York
-
Syracuse, New York, United States, 13210
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
-
Cleveland, Ohio, United States, 44106-6007
-
Columbus, Ohio, United States, 43205
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
-
-
Virginia
-
Richmond, Virginia, United States, 23298-0155
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male; 12-65 years of age
- Subjects with severe hemophilia A
- Previously treated with factor VIII for a minimum of 150 exposure days
Exclusion Criteria:
- Inhibitors to FVIII (current evidence or history)
- Any other inherited or acquired bleeding disorder in addition to Hemophilia A
- Platelet count < 100,000/mm3
- Creatinine > 2x upper limit of normal or AST/ALT (aspartate aminotransferase/alanine aminotransferase) > 5x upper limit of normal
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
|
Intravenous infusion of BAY94-9027
|
Experimental: Arm 2
Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
|
Intravenous infusion of BAY94-9027
|
Experimental: Arm 3
Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
|
Intravenous infusion of BAY94-9027
|
Experimental: Arm 4
Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
|
Intravenous infusion of BAY94-9027
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial
Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds.
A participant who had the one-time increase in dose frequency was regarded as rescued.
A rescue bleed was a bleed that occured after the dose frequency was increased.
Rescue bleeds and periods were not considered for the annualized bleeding rate (ABR).
|
On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized Number of Joint Bleeds, Trauma, Spontaneous Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A
Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
A participant who had the one-time increase in dose frequency was regarded as rescued.
A rescue bleed was a bleed that occured after the dose frequency was increased.
Rescue bleeds and periods were not considered for the ABR.
|
On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
Annualized Number of Total Bleeds in On-demand Treatment Arm and in Each Prophylaxis Arm, Part A, Extension
Time Frame: at least 100 total exposure days acquired, median time 3.9 years up to 7 years maximum
|
Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds.
|
at least 100 total exposure days acquired, median time 3.9 years up to 7 years maximum
|
Number of Participants Developed Human Coagulation Factor VIII (FVIII) Inhibitor - Part A
Time Frame: Weeks 0 to 36 during Part A
|
FVIII inhibitor testing was done according to the Nijmegen modified Bethesda assay.
A positive inhibitor test was defined with a threshold of ≥0.6 Bethesda unit (BU) at the central laboratory.
|
Weeks 0 to 36 during Part A
|
Number of Bleeds Requiring 1, 2 or >= 3 Infusions to Control the Bleed - Part A
Time Frame: Weeks 0 to 36
|
Number of bleeds requiring 1, 2 or >= 3 infusions to control the bleeding
|
Weeks 0 to 36
|
Number of Bleeds According to Locations - Part A
Time Frame: Weeks 0 -36
|
Bleed locations were categorised as joint, muscle, skin/mucosa, internal, others and missing.
|
Weeks 0 -36
|
Number of Bleeds Over Time Since Previous Prophylaxis Infusion - Part A
Time Frame: Weeks 0 to 36
|
Weeks 0 to 36
|
|
Number of Bleeds According to Participant's Assessment of Response to Treatment - Part A
Time Frame: Weeks 0 to 36 during Part A
|
Response to treatment was assessed by participant as excellent, good, moderate, poor or missing during Part A of the study.
|
Weeks 0 to 36 during Part A
|
Recombinant Human Factor VIII (rFVIII) Usage Expressed as Total Dose Per Kilogram Per Year - Part A
Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
For prophylaxis patients, the dose is related to all infusions.
|
On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion - Part A
Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
For prophylaxis patients, the dose per infusion related to prophylaxis infusion.
|
On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
Number of Participants Requiring an Increase in Dose Frequency, or Dose Increase, During Weeks 10 to 36 - Part A
Time Frame: Weeks 10 to 36 during Part A
|
Weeks 10 to 36 during Part A
|
|
Number of Surgeries According to Physician's Assessment of Adequacy of Hemostasis in Major Surgery - Part B
Time Frame: Day of surgery
|
Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.
Adequacy of hemostasis was assessed as excellent, good, moderate or poor, by the surgeon or interventionalist during Part B of the study.
|
Day of surgery
|
Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion for Major Surgery - Part B
Time Frame: Up to 3 weeks post-surgery during Part B
|
Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.
Total dose per kilogram per Infusion was expressed in international units per kilogram per infusion (IU/kg/infusion).
|
Up to 3 weeks post-surgery during Part B
|
Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions for Major Surgery - Part B
Time Frame: Up to 3 weeks post-surgery during Part B
|
Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.rFVIII
usage expressed as number of infusions and IU/kg per year, as well as IU/kg per event (surgery) was assessed by investigator.
|
Up to 3 weeks post-surgery during Part B
|
Maximum Drug Plasma Concentration (Cmax) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A
Time Frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours
|
Cmax: Maximum observed drug concentration following an infusion of 60 IU/kg
|
Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours
|
Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A
Time Frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours
|
AUC: The total area under the plasma concentration versus time curve following an infusion of 60 IU/kg .
|
Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours
|
Terminal Elimination Half Life (t1/2) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A
Time Frame: Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours
|
t1/2: Terminal half-life is the time the plasma concentration during terminal phase is halved following an infusion of 60 IU/kg .
|
Weeks 0 and 36: pre-infusion (0 hours), post-infusion 15, 30 minutes, 1, 3, 6, 8, 24, 48, 72, 96 hours
|
Overall Human Coagulation Factor VIII (FVIII) Recovery Value by Chromogenic Assay - Part A
Time Frame: Weeks 0 to 36 during Part A
|
Recovery was calculated by the following formula: Recovery = (post-infusion FVIII activity - pre-infusion FVIII activity ) * weight / dose (in IU).
Recovery is the increase of FVIII activity after the injection normalized by dose: IU/dl per IU/kg = kg/dL
|
Weeks 0 to 36 during Part A
|
Change From Baseline in Quality of Life by Hemophilia Specific Quality of Life Instrument or Questionnaire for Adults (Haemo-QoL-A) Overall Score at Week 36 - Part A
Time Frame: Week 0 (baseline) and Week 36 during Part A
|
Quality of life (QoL) was measured by the Haemo-QoL-A overall score, which ranged from 0 (the worst condition) to 100 (the best condition).
|
Week 0 (baseline) and Week 36 during Part A
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Overall Pain Severity and Interference Due to Pain at Week 36 - Part A
Time Frame: Week 0 (baseline) and Week 36 during Part A
|
Brief Pain Inventory (BPI) - Short Form (BPI-SF) was a 15-item, self-administered, validated tool developed to assess pain used in the study for patient reported outcomes.
Scores ranged from 0 to 10 and a higher score indicates a higher level of pain/interference.
|
Week 0 (baseline) and Week 36 during Part A
|
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 36 - Part A
Time Frame: Week 0 (baseline) and Week 36 during Part A
|
The WPAI is a validated instrument to assess the effect of hemophilia on ability to work, attend classes, and perform regular daily activities in participants aged 12 and above.
The WPAI also contained classroom impairment questions (CIQ).
The questionnaire was self-administered and comprised of nine questions that elicited information on work, classroom, and daily activity impairment during the previous seven days.
WPAI outcomes that are overall work and activity impairment, transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.
|
Week 0 (baseline) and Week 36 during Part A
|
Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions- Part A
Time Frame: On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
For prophylaxis patients, the dose is related to all infusions.
|
On-demand: Weeks 0 -36 and Prophylaxis: Weeks 10 - 36 during Part A
|
Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram With Prophylaxis Treatment - Part A
Time Frame: Weeks 10 - 36 during Part A
|
For prophylaxis patients, the dose per kilogram is related to prophylaxis infusions.
|
Weeks 10 - 36 during Part A
|
Number of Minor Surgeries According to Physician's Assessment of Adequacy of Hemostasis - Part A
Time Frame: Weeks 0 to 36 during Part A
|
Minor surgery was defined as any surgical procedure that did not meet the definition of major, and included simple dental extractions, incision and drainage of abscesses, or simple excisions.
|
Weeks 0 to 36 during Part A
|
Number of Surgeries According to Physician's Assessment of Response to Hemostasis, Post-surgery - Part B Main Trial
Time Frame: Up to 3 weeks post-surgery during Part B
|
Response to treatment during surgery was assessed by investigator/surgeon as excellent, good, moderate, poor or missing during Part B of the study.
|
Up to 3 weeks post-surgery during Part B
|
Number of Participants With Change/Drop in Hemoglobin/Hematocrit Laboratory Assessments - Part B
Time Frame: Up to 3 weeks post-surgery during Part B
|
Hematocrit is defined as the volume percentage (%) of red blood cells in blood.
|
Up to 3 weeks post-surgery during Part B
|
Maximum Blood Loss During Major Surgery - Part B
Time Frame: day of surgery
|
Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.
|
day of surgery
|
Number of Participants Who Took Anti-fibrinolytic Medications During Major Surgery - Part B
Time Frame: Up to 3 weeks post-surgery during Part B
|
Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.
|
Up to 3 weeks post-surgery during Part B
|
Volume of Blood Transfused in Major Surgery - Part B
Time Frame: Up to 3 weeks post-surgery during Part B
|
Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.
|
Up to 3 weeks post-surgery during Part B
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bayer Study Director, Bayer
Publications and helpful links
General Publications
- Baumann A, Piel I, Hucke F, Sandmann S, Hetzel T, Schwarz T. Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. Eur J Pharm Sci. 2019 Mar 15;130:11-20. doi: 10.1016/j.ejps.2019.01.015. Epub 2019 Jan 14.
- Lalezari S, Reding MT, Pabinger I, Holme PA, Negrier C, Chalasani P, Shin HJ, Wang M, Tseneklidou-Stoeter D, Maas Enriquez M. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia. 2019 Nov;25(6):1011-1019. doi: 10.1111/hae.13853. Epub 2019 Oct 17.
- Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, Walsch R, Lederman M, Wang M, Hardtke M, Michaels LA. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017 Mar;15(3):411-419. doi: 10.1111/jth.13597. Epub 2017 Feb 22.
- Reding MT, Pabinger I, Holme PA, Maas Enriquez M, Mancuso ME, Lalezari S, Miesbach W, Di Minno G, Klamroth R, Hermans C. Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study. Ther Adv Hematol. 2023 Apr 22;14:20406207231166779. doi: 10.1177/20406207231166779. eCollection 2023.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13024
- 2011-005210-11 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia A
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Hoffmann-La RocheActive, not recruitingSevere Hemophilia A | Moderate Hemophilia ABrazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Ireland, Morocco, Serbia
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
JW PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A Without InhibitorKorea, Republic of
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
BioMarin PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A With Anti Factor VIIIUnited States, United Kingdom, Taiwan, Korea, Republic of, Brazil, Italy
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
BayerCompletedHemophilia A; Hemophilia BIsrael
Clinical Trials on BAY94-9027
-
BayerCompleted
-
BayerCompleted
-
BayerCompletedHemophilia ABelgium, New Zealand, Netherlands, Greece, United Kingdom, Austria, United States, Italy, Romania, Bulgaria, Canada, Israel, Poland, Lithuania, Norway, Argentina, Spain
-
BayerActive, not recruitingHemophilia ACanada, Spain, United States, Belgium, Italy, Taiwan, Slovenia
-
BayerRecruitingHemophilia A | Prophylaxis of Bleeding | Treatment of BleedingKorea, Republic of
-
BayerRecruitingHemophilia A | Prophylaxis of BleedingItaly
-
BayerActive, not recruitingHemophilia ASpain, Germany, Austria, Greece, Italy, Slovenia
-
BayerActive, not recruitingHemophilia A | Children | Prophylaxis of Bleeding | Treatment of BleedingCanada, United States, Brazil, Italy, Turkey, Argentina, Norway
-
BayerActive, not recruitingHemophilia ACanada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia